SPONSOR
Supergene, LLC
Total Trials
2
Recruiting
2
Phases
Phase 3
Supergene, LLC is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Pulmonary Embolism Acute Massive, Ischemic Stroke, Acute.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Supergene, LLC
How many clinical trials has Supergene, LLC sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Supergene, LLC, of which 2 are actively recruiting participants. These trials cover conditions including Pulmonary Embolism Acute Massive, Ischemic Stroke, Acute. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Supergene, LLC research focus on?
Supergene, LLC clinical trials span Pulmonary Embolism Acute Massive, Ischemic Stroke, Acute. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Supergene, LLC clinical trial?
To participate in a Supergene, LLC trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Supergene, LLC trials with current recruitment status updated daily.
Clinical Trials by Supergene, LLC
NCT07245927
Recruiting
Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism
Pulmonary Embolism Acute Massive
NCT07324837 Phase 3
Recruiting
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Ischemic Stroke, Acute
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology